Should a pathogenic BRCA1/2-mutation be found, BC patients are at an increased risk of up to 60 % of a second primary BC (Antoniou et al. 2003; Chen and Parmigiani 2007; King et al. 2003) which may influence the choice of BC treatment (Trainer et al. 2010). The gene discussed is BRCA1; the disease is breast cancer.